

A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint

An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis

G. Kantidakis, S. Litiere, A. Neven, M. Vinches, I. Judson, P. Schoffski, S. Stacchiotti, L. D'Ambrosio, S. Marreaud, W. Van Der Graaf, M. Fiocco, B. Kasper, H. Gelderblom
On behalf of the EORTC STBSG

Disclosures

- No conflicts of interest
- Study sponsored by EORTC – STBSG

Background

- EORTC-STBSG (2002): reference values for conducting phase II STS clinical trials, Progression-Free Rate (PFR) primary endpoint
- **Goal:** Update for LMS based on a literature review!



PERGAMON

European Journal of Cancer 38 (2002) 543–549

European
Journal of
Cancer

www.ejconline.com

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

M. Van Glabbeke^{a,*}, J. Verweij^b, I. Judson^c, O.S. Nielsen^d,
on behalf of the EORTC Soft Tissue and Bone Sarcoma Group

^a*EORTC Data Center, Av Mounier 83/11, B1200, Brussels, Belgium*

^b*Rotterdam Cancer Institute and University Hospital, Groene Hilledijk 301, Rotterdam, The Netherlands*

^c*Royal Marsden Hospital, Fulham Road 203, London, UK*

^d*Aarhus Kommunehospital, Noerrebrogade 44, Aarhus, Denmark*

Eligibility criteria and endpoint

☐ **Eligible:**


- Randomized controlled or non-randomized CTs
- Phase II, III or prospective real-life studies
- Publication period: 2003 - 2018
- Adults with advanced non-resectable or metastatic STS (LMS only for the meta-analysis)
- Any systemic therapy (chemotherapy, targeted, immunotherapy or cell therapy)
- First or later lines of treatment

☐ **Non-eligible:**


- Early phase trials (phase I, I-II)
- Pediatric population
- Surgery or radiotherapy for localized disease, limb perfusion, electro chemotherapy, supportive care
- No clinical data/trial (case control studies, case series, review papers etc.)
- Retrospective clinical data
- Diagnostic or biomarker trials
- Sub-analysis, pooled analysis

❖ **Endpoint:** 3- and 6-month Progression-Free Survival (PFS)

PRISMA flow diagram



Forest plot for PFS at 6 months (pretreated patients)



*For 1 study PFS estimate for pretreated patients is only available at 3 months

ESMO Magnitude of Clinical Benefit Scale (MCBS)

- Treatment effect to target
- **MCBS**: HR = 0.65 (0.55 – 0.77) recommended for PFS

	3 months		6 months	
	Ref (P ₀)	Min target (P ₁)	Ref (P ₀)	Min target (P ₁)
First line	0.78	0.85	0.64	0.75
Pretreated	0.50	0.63	0.30	0.45

Conclusion

- ✓ Updated thresholds* for designing new studies (advanced/metastatic LMS)

Drug activity:

- ❖ For 1L patients: PFS > 64% at 6 months
- ❖ For 2L+ patients: PFS > 50% at 3 months, > 30% at 6 months

*Subject to change, data collection still ongoing

THANK YOU TO...

Those who provided PFS estimates:
(until 19/05/2020)

- Prof. **Scott M. Schuetze** (2 studies)
- Dr. **Akira Kawai** (1 study)
- Dr. **Amit Oza** (1 study)
- Prof. **Armando Santoro** (1 study)
- Dr. **Beatrice Seddon** (1 study)
- Dr. **William D. Tap** (1 study)

+ their teams!

**& all those who will provide
PFS estimates and support
the EORTC-STBSG LMS
meta-analysis!**